Safety and efficacy of a biliary-excreted angiotensin converting enzyme (ACE) inhibitor, temocapril, in combination with amlodipine in advanced diabetic nephropathy

Clinical and Experimental Nephrology

Volumn 6, Issue 4, 2002, Pages 229-236

  Yasuda, Gen ^a   Kuji, Tadashi ^a   Hasegawa, Kyoko ^a   Hirawa, Nobuhito ^a   Kihara, Minoru ^a   Toya, Yoshiyuki ^a   Shionoiri, Hiroshi ^a   Umemura, Satoshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Amlodipine; Hypertension; Pharmacokinetics; Renal function; Temocapril hydrochloride

Indexed keywords

AMLODIPINE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TEMOCAPRIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; HYPERKALEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY;

EID: 0036963835     PISSN: 13421751     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101570200039     Document Type: Article

References (23)

1. Bakris GL. Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000:36:646-61.
2. Suzuki H, Kawaratani T, Shioya H, Uji Y, Saruta T. Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS-622) in humans. Biopharm Drug Dispos 1993;14:41-50.
3. Kuroyama M, Nishikawa K, Motohashi S, Kumano K, Yago K, Komiyama T, et al. Protein binding of temocaplilat in patients with chronic renal failure. Jpn J Ther Drugs Monitor 1998;15:314-22.
4. Oguchi H, Miyasaka M, Koiwai T, Tokunaga S, Hora K, Sato K, et al. Pharmacokinetics of temocapril and enalapril in patients with various degrees of renal insufficiency. Clin Pharmacokinet 1993;24:421-7.
5. Nakashima M, Yamamoto J, Shibata M, Uematsu T, Shinjo H, Akahori T, et al. Pharmacokinetics of temocapril hydrochloride. a novel angiotensin converting enzyme inhibitor, in renal insufficiency. Eur J Clin Pharmacol 1992;43:657-9.
6. Yasuda G, Shionoiri H, Umemura S. Takasaki I. Ishii M. Exaggerated blood pressure response to angiotensin II in patients with Cushing's syndrome due to adrenocortical adenoma. Eur J Endocrinol 1994:131:582-8.
7. Tochikubo O, Uneda S, Kaneko Y. Simple portable device for sampling a whole day's urine and its application to hypertensive outpatients. Hypertension 1983;5:270-4.
8. Shioya H, Shimojo M, Kawahara Y. Determination of a new angiotensin-converting enzyme inhibitor (CS-622) and its active metabolite in plasma and urine by gas chromatography-mass spectrometry using negative ion chemical ionization. J Chromatogr 1989;496:129-35.
9. Textor SC, Novick AC, Tarazi RC, Klimas V. Vidt DG, Pohl M. Critical perfusion pressure for renal function in patients with bilateral atherosclerotic renal vascular disease. Ann Intern Med 1985;102:308-14.
10. Maschio G. Alberti D, Janin G. Locatelli F, Mann JFE, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-45.
11. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-coverting enzyme inhibitors. Arch Intern Med 1998;158:26-32.
12. Shionoiri H, Ueda S, Minamisawa K, Minamisawa M, Takasaki I, Sugimoto K, et al. Pharmacokinetics and pharmacodynamics of benazepril in hypertensive patients with normal and impaired renal function. J Cardiovasc Pharmacol 1992;20:348-57.
13. Danielson B, Querin S, LaRochelle P, Sultan E, Mouren M, Bryce T, et al. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjects. J Cardiovasc Pharmacol 1994:23(Suppl. 4):S50-S59.
14. Fruncillo RJ, Rocci ML, Vlasses PH, Mojaverian P. Shepley K, Clementi RA, et al. Disposition of enalapril and enalaprilat in renal insufficiency. Kidney Int 1987:31(Suppl 20):S-117-S-122.
15. Shionoiri H, Yasuda G, Abe Y, Yoshimura H, Kaneko Y, Shindo Y. Pharmacokinetics and acute effect on the renin-angiotensin system of delapril in patients with chronic renal failure. Clin Nephrol 1987;27:65-70.
16. Schaik BAM van, Geyskes GG, Wouw PA van, Rooij HH van, Porsius AJ. Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function. Eur J Clin Pharmacol 1988;34:61-5.
17. Debusmann ER, Pujadas JO, Lahn W, Irmisch R, Jané F, Kuan TS, et al. Influence of renal function on the pharmacokinetics of ramipril (HOE 498). Am J Cardiol 1987;59:70D-78D.
18. Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998:54:889-96.
19. Dworkin LD, Benstein JA, Parker M. Tolbert E. Feiner HD. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 1993;43:808-14.
20. Hannedouche T, Albouze G, Chauveau P, Lacour B, Jungers P. Effects of blood pressure and antihypertensive treatment on progression of advanced chronic renal failure. Am J Kidney Dis 1993;21(Suppl 2):131-7.
21. Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995:50:560-86.
22. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997:350:757-64.
23. Sheinfeld GR. Bakris GL. Benefits of combination angiotensinconverting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens 1999:12:80S-85S.